October 31, 2019
Kemin increases footprint in Egypt to globally manufacture and distribute vaccines
Kemin Industries has announced an expanded partnership with ME VAC, an animal vaccine manufacturer based in Cairo, Egypt, to further enlarge Kemin's portfolio in the global animal vaccination market.
"We believe in the importance of providing healthy and efficient solutions for animals. With a focus on transforming lives and creating a sustainable future, we know that non-antibiotic alternatives are increasingly important to our customers," said Dr. Chris Nelson, president and CEO of Kemin.
"Growing our partnership with ME VAC will enhance our ability to have a larger presence in the animal vaccine marketplace and create more innovations by expanding collaborations for R&D projects."
The new agreement increases Kemin's investment and participation with ME VAC, providing Kemin an opportunity to distribute vaccines globally, outside the Arabic-speaking countries in the Middle East. Kemin became a small investor in ME VAC several years ago.
"We are very excited to have Kemin as a trusted partner. This investment will significantly improve our capability to expand globally and drive innovation at a more rapid pace," said Dr. Magdy El Sayed, chairman and CEO of ME VAC.
Kemin continues to invest in non-antibiotic solutions in the animal health market to support the growing demand to minimise the use of antibiotics in food producing animals. With this investment, Kemin will now have access to a modern vaccine plant with production and R&D capabilities to support future growth.
"As the feed and animal production industries continue to evolve, customers are searching more aggressively for innovation that adds real value," said GS Ramesh, global group president of Kemin Animal Nutrition and Health.
"Kemin continues to be the key driver of global product and technology innovation. This new partnership will further strengthen our capability to quickly scale up new innovation, while maintaining our quality and safety standards for global regulatory requirements."